The stein-Barr virus (EBV) is a member of the genus Lymphophilus in the family Herpesviridae and is carried by more than 95% of adults. It is the causative agent of infectious mononucleosis and has also been strongly associated with the development of nasopharyngeal cancer and childhood lymphoma, and is listed as one of the human oncogenic viruses that may cause cancer. In the case of EBV infection, doctors generally recommend that patients first undergo EBV antibody testing because EBV antibody indicators are very meaningful in the diagnosis, treatment and prognosis of viral infections. In EBV infections, early infections are characterized by positive EBV capsid antigen or early antigen, while later infections are mainly characterized by positive IgG, which indicates whether the EBV infection is original or new, and is very relevant to the diagnosis, treatment, regression, and prognosis of the condition. The range of EBV antibody tests varies from laboratory to laboratory, and some laboratories with better testing can detect EBV antibodies in more detail, which is more meaningful for the diagnosis of the disease, the choice of treatment plan, and the prognosis. If the laboratory conditions are not sufficient and the number of detected antibodies is relatively low, the evolution of the antibodies can be observed.